Table 1 Subject characteristics
Control group ( n = 14) | Group A ( n = 20) | Group B ( n = 21) | P | |
|---|---|---|---|---|
Age, years | 67.9 ± 7.8 | 62.7 ± 12.0 | 64.1 ± 9.8 | 0.337 |
Sex, male (%) | 12 (85.7) | 18 (90) | 17 (81) | 0.882 |
BMI, kg/m2 | 24.0 ± 3.2 | 24.5 ± 2.8 | 23.4 ± 2.7 | 0.513 |
Disease history, years | 3 (2, 5) | 4 (2.0 , 7.8) | 2 (1 , 2) | 0.006* |
Smokers | 6 (42.9) | 7 (35.0) | 9 (42.9) | 0.884 |
Underwent stenting | 11 (78.6) | 14 (70) | 9 (42.9) | 0.080 |
Comorbid conditions | ||||
Essential hypertension | 10 (71.4) | 13 (65.0) | 16 (76.2) | 0.708 |
Diabetes mellitus | 4 (28.6) | 7 (35.0) | 4 (19.0) | 0.553 |
Hyperlipidemia | 6 (42.9) | 4 (20.0) | 4 (19.0) | 0.259 |
COPD | 1 (7.1) | 0 (0) | 0 (0) | NA |
Chronic renal failure | 0 (0) | 1 (5.0) | 2 (9.5) | NA |
Atrial fibrillation | 0 (0) | 1 (5.0) | 0 (0) | NA |
Ulcerative colitis | 0 (0) | 0 (0) | 1 (4.8) | NA |
Condition | 0.383 | |||
Stable angina pectoris | 2 (14.3) | 0 (0) | 0 (0) | |
Old myocardial infarction | 8 (57.1) | 13 (65.0) | 14 (66.7) | |
Unstable angina pectoris | 4 (28.6) | 7 (35.0) | 7 (33.3) | |
Medical therapy | ||||
Anti-platelet agents | 9 (64.3) | 11 (55.0) | 14 (66.7) | 0.774 |
Aspirin | 12 (85.7) | 17 (85.0) | 19 (90.5) | 0.883 |
Angiotensin-converting enzyme inhibitors | 7 (50.0) | 7 (35.0) | 8 (38.1) | 0.732 |
Angiotensin receptor blocker | 1 (7.1) | 4 (20.0) | 4 (19.0) | 0.659 |
β-blockers | 13 (92.9) | 18 (90.0) | 18 (85.7) | 0.872 |
Calcium channel blockers | 4 (28.6) | 6 (30.0) | 11 (52.4) | 0.281 |
Statin | 13 (92.9) | 18 (90.0) | 17 (81.0) | 0.675 |
Nitrates | 4 (28.6) | 8 (40.0) | 9 (42.9) | 0.727 |
Diuretics | 2 (14.3) | 3 (15.0) | 3 (14.3) | 1.000 |
Oral hypoglycemic agents | 3 (21.4) | 2 (10.0) | 3 (14.3) | 0.648 |
Insulin | 2 (14.3) | 2 (10.0) | 1 (4.8) | 0.623 |
Patients who experienced re-infarction | 1 (7.1) | 0 (0) | 0 (0) | NA |
Re-hospitalization | 0.461 | |||
Once | 4 (28.6) | 2 (10) | 2 (9.5) | |
Twice | 1 (7.1) | 1 (5) | 1 (4.8) | |
Thrice | 1 (7.1) | 1 (5) | 0 (0) | |
Mortality | 0 (0) | 1 (5.0) | 0 (0) | NA |
Location of ischemic target area | ||||
Ventricular septum | 11 (78.6) | 11 (55.0) | 12 (57.1) | 0.365 |
Anterior wall | 2 (14.3) | 4 (20) | 4 (19) | 1.000 |
Inferior wall | 5 (35.7) | 11 (55.0) | 14 (66.7) | 0.194 |
Posterior wall | 1 (7.1) | 3 (15.0) | 3 (14.3) | 0.771 |
Lateral wall | 2 (14.2) | 3 (15.0) | 0 (0) | 0.161 |
Number of shock wave treatment (9 times/per treatment course) | NA | 2 (1, 2.8) | 2 (1, 2.5) | 0.904 |
Duration of treatment interval, month | NA | 5 (4, 6.5) | 4 (4, 5.5) | 0.231 |